Remission of disseminated cancer after systemic oncolytic virotherapy
SJ Russell, MJ Federspiel, KW Peng, C Tong… - Mayo Clinic …, 2014 - Elsevier
SJ Russell, MJ Federspiel, KW Peng, C Tong, D Dingli, WG Morice, V Lowe, MK O'Connor…
Mayo Clinic proceedings, 2014•ElsevierMV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma
cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression.
Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple
glucose-avid plasmacytomas were treated by intravenous infusion of 10 11 TCID 50 (50%
tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy
with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient …
cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression.
Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple
glucose-avid plasmacytomas were treated by intravenous infusion of 10 11 TCID 50 (50%
tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy
with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient …
Abstract
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.
Elsevier